How I Treat CML: How to Monitor Patients and When to Consider Discontinuation of Treatment
Jerald Radich, MD, Fred Hutchinson Cancer Research Center
Friday, September 8, 2017 9:00 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Which TKI should I use in a newly diagnosed CML patient? When should I switch therapy? How and how often should I monitor disease? Is TKI discontinuation a realistic goal, and if so, how do we get there? In CML there is a near embarrassment of riches in the TKI options, all of which are excellent drugs, with specific advantages and disadvantages. Treatment response can be done relatively easily. We will develop a common sense plan to optimize therapy based on patient characteristics and treatment goals.
About the Speaker
Jerald Radich, MD, is a member of the Clinical Research Division, Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine. His laboratory work centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia, including the developing high and low tech solutions to molecular diagnostics. The Molecular Oncology Lab is a CLIA facility dedicated to performing molecular diagnostic work for national and international clinical trials.
back to top